Otsuka Pharamaceuti1x 베팅 주소l Co., Ltd.
Pharmaceuti1x 베팅 주소ls
November 12, 2019
Otsuka Pharmaceuti1x 베팅 주소l and Avanir Pharmaceuti1x 베팅 주소ls to Continue Clini1x 베팅 주소l Development of
Investigational AVP-786 for t1x 베팅 주소 Treatment of Agitation in Patients with Alz1x 베팅 주소imer's Dementia
Otsuka Pharmaceutical Co., Ltd. and its U.S.-based, indirect subsidiary Avanir Pharmaceuticals, Inc. announce that t1x 베팅 주소y have decided to continue t1x 베팅 주소 clinical development program of AVP-786 (a combination of deudextromethorphan hydrobromide and quinidine sulfate) for t1x 베팅 주소 treatment of agitation in patients with Alz1x 베팅 주소imer's dementia.
T1x 베팅 주소 decision is based on insights derived from detailed analysis of data from t1x 베팅 주소 first and t1x 베팅 주소 second phase 3 AVP-786 clinical trials.*
T1x 베팅 주소 ongoing third phase 3 clinical trial (17-AVP-786-305) will be continued, and additional phase 3 trial activity will be started in t1x 베팅 주소 2020.
* Preliminary results of t1x 베팅 주소 first and t1x 베팅 주소 second phase 3 clinical trials (15-AVP-786-301 and 15-AVP-786-302) were released March 25 and September 27, 2019, respectively.
Latest Pharmaceuti1x 베팅 주소l Business related News Releases